Insider Selling: CeriBell (NASDAQ:CBLL) VP Sells $224,433.75 in Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 9,255 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $24.25, for a total transaction of $224,433.75. Following the completion of the transaction, the vice president directly owned 34,144 shares in the company, valued at approximately $827,992. This represents a 21.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

David Foehr also recently made the following trade(s):

• On Monday, August 24th, David Foehr sold 859 shares of CeriBell stock. The stock was sold at an average price of $23.95, for a total value of $20,573.05.
• On Friday, August 21st, David Foehr sold 993 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total value of $23,851.86.

CeriBell Price Performance

Shares of NASDAQ CBLL opened at $23.63 on Friday. The firm has a market cap of $906.92 million, a P/E ratio of -13.43 and a beta of 0.95. The business’s 50 day moving average is $21.11 and its 200-day moving average is $19.64. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.33.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Equities research analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on CBLL shares. BTIG Research reiterated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research note on Friday. Raymond James Financial reaffirmed a “strong-buy” rating and set a $29.00 target price on shares of CeriBell in a report on Thursday, September 3rd. Canaccord Genuity Group lifted their price target on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Barclays upgraded CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Finally, Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and an average price target of $24.40.

Hedge Funds Weigh In On CeriBell

Hedge funds and other institutional investors have recently made changes to their positions in the company. Strs Ohio acquired a new stake in shares of CeriBell during the 1st quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd increased its stake in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of CeriBell in the 3rd quarter valued at $33,000. Tower Research Capital LLC TRC lifted its position in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares during the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of CeriBell during the 2nd quarter worth $53,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.